Close
Achema

Japan Drug Lobby Asserts Pricing Scheme Driving Drug Crisis

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Trump Order to Go Heavy on D2C Pharmaceutical Ads

US President Donald Trump is all set to order...

Is US Planning Executive Order on Chinese Pharma Companies?

It is worth noting that the pharmaceutical sector’s recent...

The Realities of the Nursing Shortage in Rural America

Along with multiple public health crises, the United States...

Green List by FDA to Cut Illegal GLP-1 Active Ingredients

The U.S. Food and Drug Administration has gone on...

For the first time in the week starting May 16th, Japan’s three major pharmaceutical trade associations joined forces to call for changes to the government’s drug pricing structure in order to prevent missing out on new drug innovation and expansion. While American and European drug companies have long complained about Japan’s socialist medical system determining drug pricing, this is the first time the domestic lobby has joined them in a cohesive force.

Japan, according to the lobbies, requires a more open and consistent cost procedure to keep the business appealing to research-focused enterprises. According to James Feliciano, Abbevie Inc.’s country manager, the system that decides how much businesses can bill hospitals and customers for pharmaceuticals has changed more than 50 times since 2015. The environmental policy in Japan has gotten largely unstable and demanding, says Feliciano, who also doubles as the president of the American lobbying group PhRMA in Japan. The Japanese market has become less appealing.

The regulations could bring back “drug lag,” he warned, pointing to a time in the early 2000s when new therapies developed outside of Japan would take four years or longer to reach the Japanese market. As per PhRMA data, international pharmaceutical investment climbed by 33% between 2015 and 2020, whilst it fell by 9% in Japan.

Latest stories

Related stories

Trump Order to Go Heavy on D2C Pharmaceutical Ads

US President Donald Trump is all set to order...

Is US Planning Executive Order on Chinese Pharma Companies?

It is worth noting that the pharmaceutical sector’s recent...

The Realities of the Nursing Shortage in Rural America

Along with multiple public health crises, the United States...

Green List by FDA to Cut Illegal GLP-1 Active Ingredients

The U.S. Food and Drug Administration has gone on...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back